L-carnitine
59,95 €
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Improved fat oxidation and energy production.
- Improved exercise performance and reduced fatigue.
- Cardiovascular health: reduces markers of atherosclerosis.
- Improving Insulin Sensitivity in Research on Type 2 Diabetes Mellitus.
- Male Fertility: Sperm Motility and Improved Sperm Count.
- Neuroprotective, with a preference for the acetyl-L-carnitine form for the CNS.
Description
L-carnitine
Metabolism / Energy
MECHANISM OF ACTION
A quaternary ammonium compound that acts as an obligatory transporter of long-chain fatty acids (LCFAs) across the inner mitochondrial membrane via the carnitine palmitoyltransferase (CPT1/CPT2) system. Essential for β-oxidation. It also removes toxic acyl groups in the form of acylcarnitines, maintaining the availability of CoA.
KEY BENEFITS
- Improved fat oxidation and energy production.
- Improved exercise performance and reduced fatigue.
- Cardiovascular health: reduces markers of atherosclerosis.
- Improving Insulin Sensitivity in Research on Type 2 Diabetes Mellitus.
- Male Fertility: Sperm Motility and Improved Sperm Count.
- Neuroprotective, with a preference for the acetyl-L-carnitine form for the CNS.
SIDE EFFECTS AND SAFETY
Gastrointestinal discomfort at high oral doses. Reactions at the subcutaneous injection site. Fishy body odor due to TMA metabolism at high oral doses. IV formulations are well tolerated.
RESEARCH AND CLINICAL NOTES
Extensive body of clinical trial evidence. Koeth et al. (NEJM 2013) raised concerns about cardiovascular risks associated with high-dose oral TMAO; fewer concerns with subcutaneous administration. Benefits for male fertility have been consistently demonstrated in infertility studies.
TARGET PROFILE:
IV therapy protocols, weight management, fertility treatments, and athletic performance programs.
Additional information
| Weight | ,26 kg |
|---|
Ingredients and Nutrition
Ingredient 1 - cucumber extract
Ingredient 2 - bilberry extract
Indications
1 capsule in the morning
You may also like…
Hot
Algal Oil Omega 3 EPA/DHA, 100 capsules
- Vegan source of Omega-3: Schizochytrium microalgae oil, a sustainable alternative to fish oil.
- Cardiovascular health: DHA and EPA help reduce triglycerides, improve circulation, and control blood pressure.
- Brain and cognitive wellness: Supports memory, concentration, and prevents cognitive decline.
- Eye health: DHA is an essential component of the retina, helping maintain optimal vision.
- Anti-inflammatory properties: Alleviates symptoms of arthritis and other chronic inflammatory diseases.
- Suitable for vegans: Free from gluten, lactose, and preservatives.
Related products
5-Amino-1MQ
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Accelerated lipolysis and fat oxidation without thermogenic effects.
- Improved mitochondrial efficiency and ATP production.
- Supports insulin sensitivity and glucose homeostasis.
- Interest in body recomposition protocols in combination with GLP-1 agonists.
- Supports NAD+ levels relevant to cellular longevity.
New
CJC-1295 5 mg without DAC + IPA 5 mg
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Synergistic optimization of endogenous GH secretion.
- Reference GH Peptide Stack for Body Composition.
- Increased lean body mass, fat loss, and recovery.
- Maintenance of the pulsatile rhythm of GH, with lower long-term risk.
- Ipamorelin's selectivity minimizes the increase in cortisol and prolactin.
MOTS-c
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- AMPK-mediated metabolic improvements, including glucose and fat utilization.
- Mimetic properties of exercise.
- Anti-inflammatory and anti-aging effects.
- Supports bone metabolism through osteoblastic activity.
- Protection against age-related physical decline.
- Potential for research on T2DM and obesity management.
New
Retatrutide 10 mg
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Body weight reduction of up to 24% in Phase II trials; the most potent in its class.
- Greater reduction in body fat compared to tirzepatide.
- Improved glycemic control through multiple mechanisms.
- Improvement in cardiovascular risk factors.
- Potential for treating NASH and reducing liver fat.
New
Retatrutide 20 mg
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Body weight reduction of up to 24% in Phase II trials; the most potent in its class.
- Greater reduction in body fat compared to tirzepatide.
- Improved glycemic control through multiple mechanisms.
- Improvement in cardiovascular risk factors.
- Potential for treating NASH and reducing liver fat.
New
Selank
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Rapid anxiolytic effect without sedation or dependence.
- Cognitive improvement: memory consolidation and processing speed.
- Mood stabilization and resilience to stress.
- Modulation of the immune system through tuftsin activity.
- Minimal side effects compared to benzodiazepines.
- Used clinically in Russia to treat anxiety and cognitive disorders.
New
Semaglutide
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Average body weight reduction of 15–17% with 2.4 mg per week.
- A 1.5–2.0% reduction in HbA1c.
- A 20% reduction in MACE in the SELECT trial among an obese, non-diabetic population.
- Remission of NASH in clinical trials.
- Reduced cravings for substances and alcohol, according to emerging data.
- Potential cognitive protection in dementia research.
New
Semax
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Cognitive improvement: memory, attention, and processing speed.
- Neuroprotection in stroke, traumatic brain injury, and cerebral ischemia.
- Upregulation of BDNF/NGF for neuroplasticity.
- Anxiolytic and antidepressant properties.
- Immune modulation.
- Excellent safety profile: non-addictive and with minimal side effects.
